---
layout: default
title: Enclomiphene
parent: 僅模型預測 (L5)
nav_order: 228
evidence_level: L5
indication_count: 10
---

# Enclomiphene
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Enclomiphene: From Secondary Hypogonadism (Investigational) to Acute Intermittent Porphyria

## One-Sentence Summary

Enclomiphene is the trans-isomer of clomiphene, a Selective Estrogen Receptor Modulator (SERM) that has been investigated in clinical trials for secondary hypogonadism in men, though it has not received regulatory approval in India or most other markets.
The TxGNN model predicts it may have potential in **Acute Intermittent Porphyria (AIP)**,
with **0 clinical trials** and **0 publications** currently supporting this specific direction — the prediction rests solely on knowledge graph inference.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Investigational: secondary hypogonadism in men (no approved indication on record) |
| Predicted New Indication | Acute Intermittent Porphyria |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L5 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, enclomiphene is the (E)-isomer of clomiphene — a Selective Estrogen Receptor Modulator (SERM) that competitively antagonises estrogen receptors in the hypothalamus and pituitary. This disrupts the negative feedback loop on gonadotropin-releasing hormone (GnRH), leading to elevated LH and FSH, which in turn stimulates endogenous testosterone production. This is why it has been explored as a non-suppressive alternative to exogenous testosterone replacement in men with secondary hypogonadism.

The biological link to Acute Intermittent Porphyria is indirect but not entirely without logic. AIP is triggered or exacerbated by hormonal fluctuations — particularly estrogen, which is known to upregulate hepatic ALA synthase (ALAS1), driving excess porphyrin precursor accumulation. A SERM that modulates estrogen receptor signalling could theoretically dampen this hormonal trigger of acute attacks. This mechanistic hypothesis exists in the broader SERM class literature.

However, it is essential to note that this specific connection has never been explored in any enclomiphene study. The TxGNN score reflects a knowledge graph co-clustering inference — likely driven by the shared node between "porphyrin metabolism" and "steroid hormone signalling" — rather than any direct experimental evidence. The prediction should be treated as a hypothesis-generating signal, not a validated mechanistic link.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for enclomiphene in acute intermittent porphyria.

---

## Literature Evidence

Currently no related literature available for enclomiphene in acute intermittent porphyria.

---

## Safety Considerations

Please refer to the package insert for safety information. Full safety data (key warnings, contraindications, and drug interaction profile) were not available in this Evidence Pack and must be retrieved from the DrugBank record and regulatory filings before any further development steps are taken.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All 10 top-ranked TxGNN predictions for enclomiphene carry an L5 evidence designation — meaning there is zero supporting clinical trial or published literature evidence for any of the predicted indications. The highest-ranked prediction (AIP) has a biologically plausible but entirely unverified mechanistic hypothesis. Without any human data, proceeding beyond hypothesis generation is premature.

**To proceed, the following is needed:**

- **Retrieve MOA data**: Pull the full DrugBank DB06735 record to confirm enclomiphene's receptor binding profile, pharmacodynamics, and known pharmacology
- **Retrieve safety data**: Download and parse the full prescribing information / SmPC from any jurisdiction where enclomiphene has been studied (e.g., FDA NDA review documents for Androxal) to extract key warnings, contraindications, and DDI profile
- **AIP mechanistic literature search**: Conduct a systematic PubMed search for "SERM + porphyria", "estrogen receptor modulation + AIP", and "clomiphene + porphyria" to assess whether any related compounds have been explored in porphyria models
- **Assess AIP clinical context**: Determine whether existing AIP therapies (givosiran, hemin) leave an unmet need that a SERM could address, and in which patient subpopulation (e.g., women with hormonally-triggered attacks)
- **Validate KG node connectivity**: Review the TxGNN knowledge graph edges connecting enclomiphene → estrogen receptor signalling → porphyrin metabolism to assess whether the prediction reflects a genuine mechanistic path or a graph clustering artefact
- **India regulatory pathway**: Confirm whether enclomiphene can be imported or investigated under clinical trial regulations in India, given its zero-registration status

> ⚠️ *This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate requires prospective clinical validation before application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

